Quantum BioPharma is trading 8.43% up now at $4.12 after momentum continued from its August 14, 2026 Q2 results and FDA approval to advance Lucid-MS into a pivotal Phase 2 trial.

  • Reported approximately US$9.5 million in combined cash, equivalents, and digital assets.
  • No newer August 17 company announcement was identified; broader markets are modestly positive, but the primary catalyst remains company-specific.